Japan okays GSK’s Sotrovimab for treating Covid-19 patients. (Reuters)
<p>
Japan has approved GlaxoSmithKline and Vir Biotechnology&#39;s Sotrovimab medicine as an antibody treatment for coronavirus, Health Minister Norihisa Tamura said on Monday.</p>
<p>
The antibody treatment is for mild to moderate COVID-19 cases which do not require oxygen supplementation, GSK said when it applied for fast-track approval this month.</p>
<p>
Sotrovimab has already been granted an emergency use approval by the FDA to facilitate the availability and use of this investigational monoclonal antibody for the treatment of COVID-19 in the U.S.</p>
<p>
GSK had claimed interim study results demonstrated an 85% reduction in hospitalisation for more than 24 hours or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial</p>
On the 4th death anniversary of human rights activist Karima Baloch, the Baloch Yakjehti Committee…
External Affairs Minister S Jaishankar will visit the US from December 24-29 to discuss key…
Students at the Bolan Medical College (BMC) in Balochistan's Quetta entered the 27th day of…
The intensifying cutting of trees for firewood in Pakistan-occupied Gilgit-Baltistan (PoGB) is not only worsening…
A group of retired judges, bureaucrats, Army officials and other civil society members have penned…
Israel and Slovakia signed a 2 billion shekel (USD 582 million) agreement on Monday to…